rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2015-11-6-558-560rpcardio-428Research ArticleEDITORIALРЕДАКЦИОННАЯThe TRIPOD Statement: how to present the results of diagnostic and prognostic studiesРЕКОМЕНДАЦИИ TRIPOD: КАК ПРЕДСТАВЛЯТЬ РЕЗУЛЬТАТЫ ДИАГНОСТИЧЕСКИХ И ПРОГНОСТИЧЕСКИХ ИССЛЕДОВАНИЙ?КолосИ. П.KolosI. P.

к.м.н., врач-кардиолог 2 кардиологического отделения ГНИЦ ПМ

docsn173@yandex.ruАничковД. А.AnichkovD. A.

к.м.н., доцент кафедры факультетской терапии им. акад. А.И. Нестерова РНИМУ им. Н.И. Пирогова

БойцовС. А.BoytsovS. A.

д.м.н., профессор, директор ГНИЦ ПМ

Государственный научно-исследовательский центр профилактической медицины 101000, Москва, Петроверигский пер., 10РоссияState Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 RussiaRussian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова 117997, Москва, ул. Островитянова, 1РоссияPirogov Russian National Research Medical University. Ostrovitjanova ul. 1, Moscow, 117997 RussiaRussian Federation201529122015116558560Copyright © Kolos I.P., Anichkov D.A., Boytsov S.A., 20152015Колос И.П., Аничков Д.А., Бойцов С.А.Kolos I.P., Anichkov D.A., Boytsov S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/428

The TRIPOD Statement aims to improve the transparency of the reporting of a prediction model study. This document describes the rationale; clarifies the meaning of each item; and discusses why transparent reporting is important, with a view to assessing risk of bias and clinical usefulness of the prediction model. To aid the editorial process and help peer reviewers and, ultimately, readers. The editorial board of "Rational Pharmacotherapy in Cardiology" hopes that the ability to publish TRIPOD will be useful to our authors, reviewers and readers.

Рекомендации TRIPOD предназначены для улучшения качества публикации результатов прогностических исследований. В документе описывается обоснование, подробно объясняется значение каждого пункта перечня и обсуждается, почему важна понятность изложения материала с акцентами на определение риска отклонений и клинической значимости прогностических моделей. Рекомендации упорядочивают процесс редактуры и помогают рецензентам, и, в конечном счете, читателям. Редакция журнала «Рациональная Фармакотерапия в Кардиологии» надеется, что возможная публикация TRIPOD будет полезна как нашим авторам и рецензентам, так и читателям.

диагностическая модельпрогностическая модельправила публикацииdiagnostic modelpredictive modelpublishing rulesReferencesCollins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 2015;162(1):55-63Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 2015;162(1):55-63Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.von Elm E, Altman DG, Egger M, et al.; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-8.von Elm E, Altman DG, Egger M, et al.; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-8.McShane LM, Altman DG, Sauerbrei W, et al.; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.McShane LM, Altman DG, Sauerbrei W, et al.; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.Gallo V, Egger M, McCormack V, et al. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement. Eur J Clin Invest 2012;42:1-16.Gallo V, Egger M, McCormack V, et al. STrengthening the Reporting of OBservational studies in Epidemiology - Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement. Eur J Clin Invest 2012;42:1-16.Bossuyt PM, Reitsma JB, Bruns DE et al. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. Radiology 2015;28:151-516.Bossuyt PM, Reitsma JB, Bruns DE et al. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. Radiology 2015;28:151-516.Janssens AC, Ioannidis JP, van Duijn CM, et al.; GRIPS Group. Strengthening the reporting of genetic risk prediction studies: the GRIPS statement. Eur J Clin Invest 2011;41:1004-9.Janssens AC, Ioannidis JP, van Duijn CM, et al.; GRIPS Group. Strengthening the reporting of genetic risk prediction studies: the GRIPS statement. Eur J Clin Invest 2011;41:1004-9.Moons KG, Royston P, Vergouwe Y, et al. Prognosis and prognostic research: what, why, and how? BMJ 2009;338:b375Moons KG, Royston P, Vergouwe Y, et al. Prognosis and prognostic research: what, why, and how? BMJ 2009;338:b375Riley RD, Hayden JA, Steyerberg EW, et al.; PROGRESS Group. Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med 2013;10: e1001380Riley RD, Hayden JA, Steyerberg EW, et al.; PROGRESS Group. Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med 2013;10: e1001380Steyerberg EW, Moons KG, van der Windt DA, et al.; PROGRESS Group. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med 2013;10:e1001381.Steyerberg EW, Moons KG, van der Windt DA, et al.; PROGRESS Group. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med 2013;10:e1001381.Reilly BM, Evans AT. Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann Intern Med 2006;144:201-9.Reilly BM, Evans AT. Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann Intern Med 2006;144:201-9.Bouwmeester W, Zuithoff NP, Mallett S, et al. Reporting and methods in clinical prediction research: a systematic review. PLoS Med 2012;9:1-12.Bouwmeester W, Zuithoff NP, Mallett S, et al. Reporting and methods in clinical prediction research: a systematic review. PLoS Med 2012;9:1-12.Perel P, Edwards P, Wentz R, Roberts I. Systematic review of prognostic models in traumatic brain injury. BMC Med Inform Decis Mak 2006;6:38.Perel P, Edwards P, Wentz R, Roberts I. Systematic review of prognostic models in traumatic brain injury. BMC Med Inform Decis Mak 2006;6:38.Shariat SF, Karakiewicz PI, Margulis V, Kattan MW. Inventory of prostate cancer predictive tools. Curr Opin Urol 2008;18:279-96.Shariat SF, Karakiewicz PI, Margulis V, Kattan MW. Inventory of prostate cancer predictive tools. Curr Opin Urol 2008;18:279-96.Altman DG. Prognostic models: a methodological framework and review of models for breast cancer. Cancer Invest 2009;27:235-43.Altman DG. Prognostic models: a methodological framework and review of models for breast cancer. Cancer Invest 2009;27:235-43.van Dieren S, Beulens JW, Kengne AP, et al. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 2012;98:360-9.van Dieren S, Beulens JW, Kengne AP, et al. Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 2012;98:360-9.Collins GS, Mallett S, Omar O, Yu LM. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med 2011;9:103.Collins GS, Mallett S, Omar O, Yu LM. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med 2011;9:103.Ettema RG, Peelen LM, Schuurmans MJ, et al. Prediction models for prolonged intensive care unit stay after cardiac surgery: systematic review and validation study. Circulation 2010;122:682-9.Ettema RG, Peelen LM, Schuurmans MJ, et al. Prediction models for prolonged intensive care unit stay after cardiac surgery: systematic review and validation study. Circulation 2010;122:682-9.Collins GS, Moons KG. Comparing risk prediction models. BMJ 2012;344:e3186.Collins GS, Moons KG. Comparing risk prediction models. BMJ 2012;344:e3186.Siontis GC, Tzoulaki I, Siontis KC, Ioannidis JP. Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ 2012;344:e3318.Siontis GC, Tzoulaki I, Siontis KC, Ioannidis JP. Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ 2012;344:e3318.Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. N Engl J Med 1985; 313:793-9.Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. N Engl J Med 1985; 313:793-9.Collins GS, Omar O, Shanyinde M, Yu LM. A systematic review finds prediction models for chronic kidney were poorly reported and often developed using inappropriate methods. J Clin Epidemiol 2013;66:268-77.Collins GS, Omar O, Shanyinde M, Yu LM. A systematic review finds prediction models for chronic kidney were poorly reported and often developed using inappropriate methods. J Clin Epidemiol 2013;66:268-77.

The authors declare that there are no conflicts of interest present.